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CeThe BLAST-AHF (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure) study is designed to test the
efficacy and safety of TRV027, a novel biased ligand of the angiotensin-2 type 1 receptor, in patients with acute heart
failure (AHF). AHF remains a major public health problem, and no currently-available therapies have been shown
to favorably affect outcomes. TRV027 is a novel biased ligand of the angiotensin-2 type 1 receptor that antagonizes
angiotensin-stimulated G-protein activation while stimulating b-arrestin. In animal models, these effects reduce
afterload while increasing cardiac performance and maintaining stroke volume. In initial human studies, TRV027
appears to be hemodynamically active primarily in patients with activation of the renin-angiotensin-aldosterone
system, a potentially attractive profile for an AHF therapeutic. BLAST-AHF is an international prospective, randomized,
phase IIb, dose-ranging study that will randomize up to 500 AHF patients with systolic blood pressure $120 mm Hg
and #200 mm Hg within 24 h of initial presentation to 1 of 3 doses of intravenous TRV027 (1, 5, or 25 mg/h) or
matching placebo (1:1:1:1) for at least 48 h and up to 96 h. The primary endpoint is a composite of 5 clinical endpoints
(dyspnea, worsening heart failure, length of hospital stay, 30-day rehospitalization, and 30-day mortality) combined
using an average z-score. Secondary endpoints will include the assessment of dyspnea and change in amino-terminal
pro–B-type natriuretic peptide. The BLAST-AHF study will assess the efficacy and safety of a novel biased ligand of
the angiotensin-2 type 1 receptor in AHF. (J Am Coll Cardiol HF 2015;3:193–201) © 2015 by the American College of
Cardiology Foundation.m the *Division of Cardiology, Duke University School of Medicine, Durham, North Carolina; yDivision of Cardiology, Stony
ok University, Stony Brook, New York; zDepartment of Emergency Medicine, Vanderbilt University, Nashville, Tennessee;
omentum Research, Inc, Durham, North Carolina; kCanadian VIGOUR Centre at the University of Alberta, Edmonton, Alberta,
nada; {Department of Cardiology, Athens University Hospital Attikon, Athens, Greece; #Department of Emergency Medicine
d Cardiovascular Research Institute, Wayne State School of Medicine, Detroit, Michigan; **Cardiology, Department of Medical
d Surgical Specialties, Radiological Sciences and Public Health; University of Brescia, Brescia, Italy; yyDepartment of Cardiology,
dical University, Clinical Military Hospital, Wroclaw, Poland; zzTrevena, Inc., King of Prussia, Pennsylvania; xxSection of
rdiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California-San Francisco, San
ncisco, California; kkDepartment of Cardiology, University of Groningen, Groningen, the Netherlands; and the {{Department
Emergency Medicine, Indiana University School of Medicine, Indianapolis, Indiana. The BLAST-AHF study is funded by Tre-
na, Inc. Dr. Felker has received grant support from the National Heart, Lung, and Blood Institute, Novartis, Roche Diagnostics,
suka, and Amgen; and has served as a consultant to Trevena, Amgen, Novartis, Celladon, Sorbent, Bristol-Myers Squibb, Sin-
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194A cute heart failure (AHF) remains amajor public health problem, withmore than 1 million hospitalizations
occurring annually in the United States and
over 4 million worldwide (1,2). Nearly 35%
of patients will die or be rehospitalized
within 90 days after discharge. Despite over
2 decades of efforts, no new therapies for
this syndrome have conclusively demon-
strated symptom relief or improved hospital
course or post-discharge morbidity or mor-
tality (3). None of the currently-available
therapies, including diuretic agents, vasodi-
lators such as nitrates or nesiritide, or
inotropic agents such as milrinone or dobut-
amine, have been shown to favorably alterthe natural history of AHF. Indeed, convincing evi-
dence for even clinically-important symptomatic
benefits with any of the currently-available AHF
treatments is lacking (4). Thus, there remains a major
unmet need to develop new therapies for AHF.
AHF is associated with acute symptoms (primarily
dyspnea), an unpredictable in-hospital course char-
acterized by events such as worsening heart failure
(HF), and a high rate of post-discharge adverse
events such as recurrent hospitalizations and death.
Ideally, an effective AHF therapy would provide rapid
and durable improvement in symptoms as well as
improve both in-hospital course and post-discharge
outcomes (5).
Fully capturing the effect of a therapy on each of
these treatment goals in the context of a clinical trial
has been a major challenge in trial design, and there
remains no consensus about the ideal endpoint for
clinical trials in AHF. Past clinical trials have gener-
ally focused on short-term symptom relief in the
belief that short-term intravenous (IV) therapy was
unlikely to substantially alter the long-term courseupport from the NIH/National Heart, Lung, and Blood Instit
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study, in which serelaxin showed reductions in
6-month cardiovascular morality, have challenged
this belief, and these results are now being tested in
the larger ongoing RELAX-AHF2 study (9). Trial
design is even more challenging for early-phase
studies, as there is no reliable surrogate for clinical
efficacy and safety for AHF that can provide clear
guidance for dose selection or reliably predict out-
comes in phase III studies (10).
RENIN-ANGIOTENSIN-ALDOSTERONE
SYSTEM MODULATION IN AHF
Activation of the renin-angiotensin-aldosterone sys-
tem (RAAS) is one of the fundamental aspects of
HF pathophysiology. Through angiotensin II (AngII),
RAAS increases vascular tone and stimulates the
kidney to retain both sodium and water. In the setting
of normal cardiac function and fluid depletion, these
effects help to maintain cardiac output; however,
when cardiac function is impaired, the increase in
pre-load and afterload produced by AngII becomes
maladaptive, chronically increasing hemodynamic
strain on the failing heart. AngII also has direct effects
on the myocardium and interstitium, leading to
myocyte hypertrophy, interstitial collagen deposi-
tion, and adverse remodeling. Inhibition of the
RAAS system, either through inhibiting the con-
version of angiotensin 1 to AngII (through inhibi-
tion of the angiotensin-converting-enzyme [11]) or
direct blockade of the angiotensin receptor (using
angiotensin-receptor blockers [ARBs] [12]), has pro-
ven long-term beneficial effects in patients with
chronic systolic HF as well as post-myocardial in-
farction left ventricular dysfunction. RAAS activation
is greater in patients during HF decompensation
(13); however, there are minimal data on the acuteute, Cardiorentis, Abbott Point-of-Care, Novartis,
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195use of drugs that target RAAS activation. In
the CONSENSUS-2 (Cooperative New Scandinavian
Enalapril Survival Study-2), which studied IV ena-
laprilat in acute myocardial infarction with subgroup
analysis for patients with pulmonary edema and HF
after admission, no benefits were observed in the
overall study population or in the pre-specified
subgroups. Substantially higher rates of hypotension
and worsening renal function were seen in the
enalaprilat-treated patients (14). Other smaller stu-
dies in patients with AHF without myocardial
infarction have suggested potential therapeutic ben-
efits (15,16). A small, randomized, double-blind,
placebo-controlled trial tested the efficacy and
safety of IV enalaprilat in 20 patients with acute
pulmonary edema unrelated to acute myocardial
infarction (15). Compared with placebo, enalaprilat
led to greater reduction in pulmonary capillary wedge
pressure (37% vs. 10%) as well as improved renal
blood flow, without excessive hypotension or adverse
effects. A recent trial of subacute RAAS inhibition
with the direct renin inhibitor aliskiren in patients
after initial stabilization for AHF did not show benefit
in post-discharge outcomes (17). Overall, it remains
unknown whether the hemodynamic and neurohor-
monal blocking effects of acute RAAS inhibition
would be beneficial in AHF, although such an
approach has theoretical appeal given the role of
RAAS activation in HF in general.
BIASED LIGANDS OF
G-PROTEIN-COUPLED RECEPTORS
G-protein-coupled receptors (GPCRs) have been tar-
gets for drug discovery in diverse therapeutic
areas. GPCRs activate a broad network of downstream
effects comprised of parallel signal transduction
pathways. The angiotensin II type I receptor (AT1R), a
GPCR, mediates the biological effects of AngII.
Although traditionally thought to mediate all of their
biological effects through G-protein signaling path-
ways, it is now apparent that other signaling path-
ways mediated by b-arrestins play a role in
downstream signaling of GPCRs, including AT1R. The
2 b-arrestin isoforms (b-arrestin-1 and -2), both of
which desensitize G-protein signals, promote recep-
tor internalization (18) and can activate a range of
downstream signaling pathways, including mitogen-
activated protein kinase and phosphoinositide
3-kinase pathways (19). The discovery that these
pathways can independently modulate ligand effects
was a major advance, but more recent work uncov-
ered activation of a subset of receptor signaling
pathways that can be selected at the level of theligand. This opened the door for the development of a
new class of functionally selective drugs, “biased
ligands,” which aim to preserve beneficial effects
while reducing unwanted effects (20).
For the AT1R, signaling mediated by Gq, 1 of the
family of heterotrimeric G proteins, has been shown
to mediate vasoconstriction (21) and cardiac hyper-
trophy (22), whereas b-arrestin-2 recruitment to the
receptor results in modest positive inotropy, receptor
desensitization and internalization, and activation
of antiapoptotic signals. ARBs block both of these
pathways equally, with the net effect being a benefi-
cial reduction in vascular tone, but at the expense
of blocking potential positive effects on cardiac
contractility and cardioprotective signals. It has been
reported that b-arrestin biased ligands at the AT1R
can stimulate cardiomyocyte proliferation (23), acti-
vate the pro-survival kinase Akt (24), reduce cardiac
apoptosis caused by mechanical stretch or ischemia/
reperfusion injury in mice (25), and promote
contractility in vitro in a b-arrestin–dependent
manner (26). In addition, these ligands promote AT1R
and b-arrestin–dependent cardiomyocyte contrac-
tility in mice (25), likely by increasing calcium sensi-
tivity of cardiac myofilaments (27). Therefore, a
b-arrestin biased ligand at the AT1R could produce
vasodilation by blocking the Gq pathway while
simultaneously promoting beneficial cardiac effects
through b-arrestin signaling.
TRV027:
A NOVEL “BIASED” RAAS MODULATOR
TRV027 is a biased ligand of AT1R, antagonizing
angiotensin-stimulated G-protein activation while
stimulating b-arrestin (Figure 1). In normal rats,
TRV027 reduces afterload while increasing cardiac
performance and maintaining stroke volume. This
contrasts with classical ARBs, which in normal ani-
mals, decrease cardiac contractility, cardiac output,
and stroke volume (28). In large animal models of HF,
TRV027 has been shown to be a potent, balanced
vasodilator that enhances cardiac output and pre-
serves glomerular filtration rate while decreasing
renal vascular resistance and increasing renal blood
flow (29,30). In theory, TRV027 would allow the
beneficial effects of RAAS blockade while avoiding
potentially negative effects on cardiac performance, a
profile of hemodynamic effects that is inherently
attractive for the treatment of AHF.
Prior human studies of TRV027 have included
small, early phase studies in normal volunteers (31) as
well as a phase IIa study in patients with New York
Heart Association functional class III to IV HF and
FIGURE 1 Mechanistic Hypothesis of TRV027 at Angiotensin Receptor
TRV027 antagonizes G-protein-mediated signaling (vasoconstriction, fluid retention) but agonizes beta-arrestin mediated signaling
(increased cardiac contractility and cardioprotection). Ang ¼ angiotensin; AT1R ¼ angiotensin II type 1 receptor; GRK ¼ G-protein-coupled
receptor kinase.
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196elevated filling pressures (pulmonary capillary wedge
pressure $20 mm Hg) (32). These early data demon-
strate that TRV027 was well tolerated, had a predict-
able pharmacokinetic profile, and produced a rapidly
reversible, dose-related decrease in mean arterial
pressure without any adverse safety signals. Effects
on pulmonary capillary wedge pressure were noted
primarily in patients with RAAS activation (based on
measured plasma renin activity). Loop diuretic agents
may further activate RAAS, potentially worsening this
core pathophysiologic characteristic of AHF. The dif-
ferential effects of TRV027 based on RAAS activation
are potentially appealing for both safety and efficacy
reasons, because only those patients with the tar-
geted pathophysiology will likely respond to the
drug, unlike existing vasodilators. Consistent with
this hypothesis, normal human and chronic HF
studies demonstrated attenuated hemodynamic ef-
fects in patients with low plasma renin activity. Its
rapid onset of action and reversibility (approximately
2-min half-life) both support the potential titratability
of this agent, unlike classical ARBs, which have a
much longer half-life. Taken together, these data
support the ongoing development of TRV027 as a
treatment for patients with AHF. The efficacy and
safety of this approach is currently being tested in
an international phase IIb randomized clinical trial,BLAST-AHF (Biased Ligand of the Angiotensin
Receptor Study in Acute Heart Failure).
DESIGN OF THE BLAST-AHF STUDY
BLAST-AHF is an international, randomized, double-
blind, placebo-controlled, dose-ranging phase IIB
study designed to evaluate the overall safety and
efficacy of TRV027, when administered in addition to
standard of care, on morbidity and mortality, acute
symptoms, and in-hospital clinical course in patients
hospitalized with AHF. The overall study design is
described in Figure 2. A total of up to 500 patients are
planned for enrollment at over 70 sites in 12 coun-
tries, with the first patient enrolled in December 2013
(NCT01966601). All study sites will have approval
from their local ethics committee or institutional re-
view board, as well as applicable country and local
regulatory approval. The BLAST-AHF study is being
conducted under the International Committee on
Harmonization Good Clinical Practice Consolidated
Guideline. All patients enrolled in the BLAST-AHF
study will provide written informed consent. The
study will be led by an academic steering committee
composed of experts in AHF.
STUDY POPULATION. Inclusion and exclusion cri-
teria for the BLAST-AHF study are summarized in
FIGURE 2 Schematic of Study Design for the BLAST-AHF Study
AHF ¼ acute heart failure; BLAST-AHF ¼ Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure.
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197Table 1. Patients must present with dyspnea at rest or
with minimal exertion, have elevated natriuretic
peptide levels (with distinct natriuretic peptide
criteria for those with atrial fibrillation or obesity),
and at least one of the following additional signs or
symptoms: radiographic evidence of pulmonary
congestion, rales, elevated jugular venous pressure,
or peripheral edema. All enrolled subjects must, in
the opinion of the investigator, have a high likelihood
of requiring at least 48 h of hospital-based AHF
treatment. Randomization will occur no sooner than 1
h after at least 40 mg of IV furosemide (or equivalent
loop diuretic) to ensure patients remain symptomatic
(e.g., dyspnea at rest or with minimal exertion) after
initial presentation, and no later than 16 h after the
first recorded systolic blood pressure measurement.
Systolic blood pressure at entry must be between 120
and 200 mm Hg. Enrollment as early as possible in the
clinical course is strongly emphasized, and ideally,
patients will be enrolled within 6 h of presentation.
Of note, ejection fraction is not an inclusion criterion;
however, patients must have a history of chronic HF
treated for at least 30 days. Given the hypothesis that
TRV027 may provide renal protection, study subjectsmust have estimated glomerular filtration rate be-
tween 20 and 75 ml/min/1.73 m2.
Given the mechanism of TRV027, any patient on
ARBs within 7 days of randomization will be ex-
cluded, although the angiotensin-converting enzyme
inhibitors are permitted. Although concomitant ARB
use is not anticipated to be a contraindication to
the use of TRV027, ARBs were excluded in this
study to avoid confounding the dose response to
TRV027. Concomitant IV nitroprusside, nesiritide, or
vasopressor within 2 h of randomization is an exclu-
sion criterion. For inotropes, use for at least 4 h
before randomization or planned use within 48 h of
randomization is an exclusion criterion. However,
use of dopamine <2.5 mg/kg/min is allowed for any
duration of time before or planned after randomiza-
tion, as long as it was not used within 2 h of
randomization. Intravenous nitrates (nitroglycerin at
a dose >0.1 mg/kg/h or equivalent) or any IV nitrates
if the patient’s screening systolic blood pressure
is <150 mm Hg within 1 h before randomization, is
an exclusion criterion. In patients with systolic blood
pressure >150 mm Hg, doses of IV nitrates #0.1
mg/kg/h are permitted.
TABLE 1 Inclusion Criteria
Inclusion criteria—patients may be included in the study if all of the following criteria are met:
Men or women age $21 and #85 yrs
Women of non–child-bearing potential must have:
 Documentation of surgical sterilization (hysterectomy and/or bilateral
oophorectomy) OR
 Experienced menopause: no menses for >12 months
Women of child bearing potential must have:
A negative pregnancy test, AND
Had their most recent menstrual period $2 weeks before presentation
Able to provide written informed consent
Pre-existing diagnosis of HF (treated by stable, HF therapy consistent with American College
of Cardiology/American Heart Association and European Society of Cardiology practice
guidelines for the treatment of chronic heart failure for at least 30 days before screening
including any of the following classes of medications: diuretic agents, ACE inhibitors, beta-
adrenergic blockers)
Systolic blood pressure $120 and #200 mm Hg within 30 min of randomization
Ventricular rate #125 beats/min. Patients with rate-controlled persistent or permanent AF at
screening are permitted.
Presence of ADHF defined by:
 BNP >400 pg/ml or NT-proBNP >1,600 pg/ml
 For patients with BMI >30 kg/m2: BNP >200 pg/ml or NT-proBNP >800 pg/ml
 For patients with rate-controlled persistent or permanent AF: BNP >600 pg/ml
or NT-proBNP >2,400 pg/ml
 AND at least 2 of the following:
Congestion on chest radiograph
Rales by chest auscultation
Edema $þ1 on a 0 to 3þ scale, indicating indentation of skin with mild digital
pressure that requires 10 s or more to resolve in any dependent area including
extremities or sacral region.
Elevated jugular venous pressure ($8 cm H2O)
Receipt of an IV loop diuretic agent at a minimal dose of 40 mg furosemide (or equivalent loop
diuretic agent) for the treatment of dyspnea due to ADHF at least 1 h before anticipated
randomization and the initiation of study medication
Patient report of dyspnea at rest or upon minimal exertion during screening at least 1 h after
administration of IV loop diuretic agent
ACE ¼ angiotensin-converting enzyme; ADHF¼ acute decompensated heart failure; AF¼ atrial fibrillation; BMI¼
body mass index; BNP ¼ B-type natriuretic peptide; HF ¼ heart failure; IV ¼ intravenous; NT-proBNP ¼ amino-
terminal pro–B-type natriuretic peptide.
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198STUDY TREATMENT. Patients will be randomly
assigned in a double-blind fashion to either placebo
or to 1 of 3 dose levels (1, 5, 25 mg/h) of TRV027 (1:1:1:1
randomization). Study drug will be given as a
continuous infusion for at least 48 h and up to 96 h
(precise duration at investigator’s discretion). Three
hours before termination of study drug infusion, the
infusion rate will be reduced by 50%. Patients will be
evaluated throughout the infusion period, with
formal assessments at day 5, hospital discharge, and
day 30. Patients will be followed up to 180 days for
vital status.
Excessive hypotension during AHF treatment has
been identified as a major safety concern and has
limited the development of other potentially prom-
ising AHF therapies (33). To reduce the risk of hypo-
tension, careful blood pressure monitoring and study
drug dose adjustment criteria have been imple-
mented in the BLAST-AHF study. Blood pressure will
be measured hourly through the first 6 h of study
drug infusion, then every 3 h through hour 12, every6 h through hour 72, and every 8 h through the end of
infusion. The actions listed in the following text will
be taken if a patient experiences a decrease in blood
pressure at any time during study drug infusion:
 Patients that experience symptomatic hypotension
will have study drug permanently discontinued.
 Patients who experience a systolic blood pre-
ssure #95 mm Hg (confirmed by a second reading
within 10 min) at any time during study drug
infusion will have study drug permanently
discontinued.
 Patients who experience a decrease of more than
40 mm Hg (confirmed by a second reading within
10 min) in systolic blood pressure from their pre-
dose baseline but remain asymptomatic will have
the study drug infusion rate decreased by 50%.
For patients experiencing an episode of decreased
blood pressure requiring study drug dose reduction or
discontinuation, additional blood pressure moni-
toring will be performed every one-half hour through
2 h and hourly through 5 h following the study drug
dose change. If a reduction in study drug is required,
the dosage of study drug cannot be increased at any
time thereafter.
ENDPOINTS. Designing endpoints for phase II
studies in AHF that can capture the various clinical
domains of potential interest has been a significant
challenge in drug development (3). For the BLAST-
AHF study, the primary endpoint will be a compos-
ite of 5 clinical outcomes: 1) time from randomization
to death through day 30; 2) time from randomization
to HF re-hospitalization through day 30; 3) time from
randomization to worsening HF through day 5;
4) change in dyspnea visual analog scale (VAS) score
(calculated area under the change from baseline
curve) from baseline through day 5; and 5) length of
initial hospital stay (in days) from randomization.
These component outcomes will be combined by
deriving an average z-score (34) for each patient as
further described in the following text.
Lack of standardized assessment of dyspnea has
been a methodological limitation in some prior AHF
studies (35). In the BLAST-AHF study, dyspnea as-
sessments will be performed under standardized
conditions, with the patients’ physical position at
each dyspnea assessment documented in their source
records and assessed with the same procedure
throughout the study. The assessment will be done
after the patient has rested without supplemental
oxygen for 3 to 5 min lying in bed with legs level and
the head of the bed raised to 30. If the patient does
not tolerate removal of supplemental oxygen and/or
TABLE 2 Exclusion Criteria
Exclusion criteria—patients will be excluded if any of the following apply:
Women who are pregnant or breast-feeding
Clinical presentation
 Suspected ACS on the basis of clinical judgment or coronary revascularization in the
3 months before screening or planned during current admission. NOTE: the pres-
ence of elevated troponin concentrations in the absence of other clinical findings is
not sufficient for a diagnosis of ACS
 Temperature >38.5C (oral or equivalent) or suspected sepsis or active infection
requiring IV antimicrobial treatment
 Clinically-significant anemia (hematocrit <25%)
 Current or planned ultrafiltration, paracentesis, hemofiltration, or dialysis at time
of screening
 Any mechanical ventilation requiring tracheal intubation and sedation at the time
of screening or during the current hospitalization
 CPAP/BiPAP discontinued <1 h before randomization, unless prescribed for treat-
ment of sleep apnea and used for >3 months
 History or current use of left ventricular assist devices or intra-aortic balloon
pumps
 Administration of intravenous radiographic contrast agent within 72 h before
screening or presence of acute contrast induced nephropathy at the time of
screening
 Presence of clinically-significant arrhythmia that, in the investigator’s opinion,
is the primary cause of WHF symptoms, including ventricular tachycardia or
bradyarrhythmia with ventricular rate <45 beats/min
 Uncertainty about ability to complete follow-up including (but not limited to)
alcoholism, severe drug abuse, homelessness, unknown or uncertain residency
status, and so on.
Medications
 Use of intravenous nitroprusside or nesiritide within 2 h before randomization
 IV nitrates (nitroglycerin at a dose >0.1 mg/kg/h or equivalent) or any IV nitrates if
the patient’s screening systolic blood pressure is <150 mm Hg within 1 h before
randomization
 Use for at least 4 h or planned use of inotropes (milrinone, levosimendan,
dobutamine, or >2.5 mg/kg/min dopamine), within 48 h before randomization or
any use of IV inotropes or vasopressors within 2 h before randomization
 Use of ARBs within 7 days before randomization. ACE inhibitors are permitted.
 Use of any investigational medication within 30 days or 5 terminal elimination half-
lives (whichever is longer) before randomization
 As determined by the investigator, clinically significant hypersensitivity, allergy to,
or intolerance of ARBs
Medical history
 Any significant pulmonary disease that requires steroid IV or inhalation therapy,
is known to significantly affect pulmonary function tests, or led in the past to
respiratory failure.
 Major surgery within 8 weeks before screening
 Stroke within 3 months before screening
 eGFR (sMDRD) <20 ml/min/1.73 m2 or >75 ml/min/1.73 m2 between presentation
and randomization
 Post-cardiac or renal transplant
 Listed for renal transplant or cardiac transplant with anticipated transplant time to
transplant <6 months
 History of severe left ventricular outlet obstruction (either valvular or sub-
valvular), severe mitral valve stenosis, or any other surgically-correctable valvular
disease as the primary cause of AHF, with the exception of mitral regurgitations
secondary to left ventricular dilation
 Complex congenital heart disease
 Diagnosis of hypertrophic or restrictive cardiomyopathy
 In the opinion of the investigator, significant pulmonary or hepatic disease that
could interfere with the evaluation of safety or efficacy of TRV027
 In the opinion of the investigator, has a life expectancy of <6 months including
significant malignant or premalignant conditions known to substantially limit
prognosis
ACS ¼ acute coronary syndrome; AHF ¼ acute heart failure; ARB ¼ angiotensin-receptor blocker; BiPAP ¼ bilevel
positive airway pressure; CPAP ¼ continuous positive airway pressure; eGFR ¼ estimated glomerular filtration
rate; sMDRD ¼ simplified Modification of Diet in Renal Disease formula; WHF ¼ worsening heart failure; other
abbreviations as in Table 1.
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199the bed position, oxygen will be replaced and/or the
bed raised and the patient asked to report the dys-
pnea severity at the point when the oxygen was off
and the bed was reclined. Dyspnea by VAS will be
assessed at baseline as well as at 3, 6, 24, 48, 72, and
96 h/end of study drug infusion. Secondary efficacy
endpoints are: 1) the change in dyspnea VAS scores
(calculated area under the curve representing the
change from baseline over time) from baseline
through day 5; and 2) the change in amino-terminal
pro–B-type natriuretic peptide (measured at a cen-
tral core laboratory) from baseline to 48 h. Other
exploratory analyses will be undertaken to evaluate
the efficacy, safety, and tolerability of TRV027 in pre-
defined subgroups of patients with AHF. A detailed
list of efficacy assessments is provided in Table 2.
SAFETY MEASURES. Safety endpoints will include:
1) all-cause mortality through day 180; 2) the inci-
dence of treatment-emergent adverse events and
serious adverse events; 3) changes in vital signs
including the incidences of asymptomatic and
symptomatic hypotension; and 4) changes in labora-
tory values from baseline. Asymptomatic reduction in
systolic blood pressure is defined as a drop to <95
mm Hg or a decrease from baseline of >40 mm Hg
without symptoms; symptomatic reduction in sys-
tolic blood pressure is defined as <95 mm Hg or by a
decrease from baseline of >40 mm Hg along with
symptoms such as lightheadedness or dizziness.
Clinical safety data from adverse event reporting,
clinical observations, 12-lead electrocardiograms,
findings from cardiac telemetry monitoring, vital
signs (blood pressure, heart rate, respiratory rate,
and oral temperature), oxygen saturation, and safety
laboratory tests will be summarized, and any
clinically-significant abnormalities will be described.
An independent data safety and monitoring board will
oversee the safety of patients throughout the trial.
STATISTICAL ANALYSIS AND POWER. The primary
efficacy measure is a composite of 5 clinical endpoints
described in the previous text, combined using an
average z-score. This framework allows the combi-
nation of multiple clinical endpoints into a single
statistical assessment, without assigning a rank of
relative importance to each domain as is required
with other related methods (36,37). O’Brien (38) had
proposed that simple or weighted summation of sin-
gle endpoints with standard procedures leads to
asymptotically normal statistics. The average z ex-
tends this approach to include continuous, ordinal,
dichotomous, and time-to-event endpoints. Specif-
ically, continuous, ordinal, and dichotomous vari-
ables are converted to z-scores by subtracting anindividual’s value from the overall mean and dividing
by the SD of the pooled group; time-to-event vari-
ables are first transformed to log-rank scores (39) and
then converted to z-scores by subtracting the mean
TABLE 3 Estimated Treatment Effects Used for Power Calculations
Endpoint Placebo Active
Death 30 days post-randomization (event rate) 7% 4%
Heart failure rehospitalization at 30 days (event rate) 14% 13%
Worsening heart failure at 5 days (event rate) 20% 11.5%
Visual analog scale area under the curve through
day 5 (mean mm-h)
1,680 2,250
Length of initial hospital stay (mean days) 10 8.2
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z-scores are then aligned to the same direction so that
worse outcomes have smaller scores. The z-scores are
then averaged across endpoints for each patient.
Treatment groups will be compared with respect to
this average z-score, the primary efficacy outcome,
using the Wilcoxon rank-sum test. An interim anal-
ysis of the efficacy and safety data will take place
after approximately 300 patients have been exposed
to the study drug. Using a combination of qualita-
tive and quantitative methods, the best TRV027
dose will then be selected to continue in the
remaining 200 patients (TRV027 or placebo in a 1:1
randomization scheme). This will result in a total of
approximately 175 placebo patients and 175 active
patients treated with the selected TRV027 dose.Based on simulations and assuming a modest cor-
relation among the endpoints, a total of 175 placebo
and 175 active patients provides approximately 79%
power at the 2-sided 0.05 significance level to detect
the following treatment effects across the 5 compo-
nents of the primary clinical composite endpoint
(Table 3).
CONCLUSIONS
The BLAST-AHF study will test a novel, biased
ligand pharmacologic intervention based on evolving
understanding of the biology of GPCRs. The overall
clinical course of subjects in the trial will be assessed
using an innovative endpoint framework, evaluating
the response to therapy across multiple domains
of interest, including acute symptoms, in-hospital
clinical course, and post-discharge outcomes. The
results of the BLAST-AHF study will inform de-
cisions about dose selection and study design for
further development of TRV027 as a novel thera-
peutic agent for AHF.
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